LANCY(SZ:002612)2022-04-22 16:00Dividend and Financial Performance - The company plans to distribute a cash dividend of 0.70 CNY per 10 shares to all shareholders based on a total share capital of 442,445,375 as of December 31, 2021[5]. - The company's operating revenue for 2021 was approximately ¥3.67 billion, representing a 27.42% increase compared to ¥2.88 billion in 2020[27]. - The net profit attributable to shareholders for 2021 was approximately ¥187.45 million, an increase of 31.97% from ¥142.04 million in 2020[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥184.16 million, reflecting an 82.00% increase from ¥101.19 million in 2020[27]. - The net cash flow from operating activities for the year 2021 was CNY 470,584,897.30, representing an increase of 24.07% compared to CNY 379,278,066.80 in 2020[28]. - Basic and diluted earnings per share for 2021 were CNY 0.4237, up 31.42% from CNY 0.3224 in 2020[28]. - The total assets at the end of 2021 reached CNY 6,850,751,362.79, a 32.93% increase from CNY 5,153,564,692.50 at the end of 2020[28]. Medical Beauty Segment - The company has a total of 100% ownership in several subsidiaries, including Sichuan Milan and Shenzhen Milan, which are part of its medical beauty segment[16]. - The company holds a 60% stake in Xi'an Milan, further expanding its presence in the medical beauty industry[16]. - The company has established a significant number of subsidiaries in the medical beauty sector, indicating a strong market expansion strategy[16]. - The company is focused on developing new products and technologies within its medical beauty division, aiming to enhance its market position[16]. - The medical beauty business has seen rapid growth, with a nationwide strategic expansion and improved operational management capabilities[44]. - The company operates 28 medical beauty institutions, including 5 comprehensive hospitals and 23 clinics, primarily located in major cities[68]. - Milan Baiyu, a high-end medical beauty brand, has served over 700,000 clients and has been recognized as one of the top ten medical beauty hospitals in Chengdu[69]. - The medical beauty segment achieved revenue of RMB 1,119.93 million, a year-on-year increase of 37.84%[76]. - Gross profit for the medical beauty segment was RMB 580.50 million, with a gross margin of 51.83%, down 2.50% year-on-year[76]. - Non-surgical medical beauty services accounted for 73.86% of the medical beauty revenue in 2021[112]. Women's Apparel Segment - The company operates in the mid-to-high-end women's clothing sector, which is experiencing a trend towards multi-brand operations and increased market concentration[39]. - The company emphasizes the importance of product quality, style, and consumer experience in the competitive landscape of the women's apparel market[40]. - The women's apparel segment achieved revenue of 1.691 billion CNY, a year-on-year increase of 27.86%[62]. - Gross profit for the women's apparel segment reached 1.033 billion CNY, with a gross margin of 61.08%, up 7.43% from the previous year[62]. - The online sales channel for women's apparel generated total revenue of 335 million CNY, representing a year-on-year growth of approximately 20%[66]. - The company operates seven proprietary women's clothing brands, focusing on differentiated product positioning and design styles to meet diverse consumer needs[45]. - The LɅNCY brand has undergone a brand upgrade, emphasizing women's individuality and empowerment through its new product lines[46]. - The company has established a multi-brand matrix to cater to the differentiated fashion demands of women across various age groups[41]. Market Trends and Strategies - The market for mid-to-high-end women's clothing is projected to grow, with retail sales expected to rise from 22.6% in 2018 to 23.4% by 2023[39]. - The company has outlined its future development plans, which include potential market expansion and strategic acquisitions[5]. - The company aims to expand its medical beauty services nationally, having established a strong presence in Southwest China[68]. - The company has implemented a three-tier operational management system to optimize management as the business expands[78]. - The company is focused on developing a standardized operational system across its medical beauty brands to ensure quality and safety[76]. - The company aims to leverage policies promoting new consumption and product innovation to drive high-quality development in the domestic clothing market[200]. Research and Development - The company has applied for 10 invention patents and 25 utility model patents in the medical beauty sector during the reporting period[101]. - The company has invested in R&D projects aimed at improving product quality and reducing production costs, including a new structure for decorative chains in clothing[151]. - The company's R&D investment increased by 20.84% to ¥112,549,448.81 in 2021, compared to ¥93,137,288.37 in 2020[159]. - The company has filed multiple patents in 2021, including a new optical treatment device and a breast lifting wire ruler, aimed at enhancing operational efficiency and patient comfort[157]. Financial Management and Investments - The company reported a significant increase in investment income, contributing 29.73% to total profit, primarily from joint venture investments and financial management gains[162]. - The total investment for the reporting period was ¥2.51 billion, a 32.72% increase compared to the previous year[169]. - The company has established several new subsidiaries during the reporting period, including Chengdu Jinjing Skin Medical Beauty Clinic, with no significant impact on overall operations and performance[194]. - The company has not encountered any issues or other situations regarding the use and disclosure of raised funds[186]. Market Outlook - The continuous growth of disposable income and the increase in high-net-worth individuals provide strong momentum for the development of the mid-to-high-end women's and children's clothing markets, as well as the medical beauty industry[198]. - The clothing industry is expected to experience a low-speed operational trend in 2022 due to a high base effect from 2021 and a more complex macroeconomic environment[200]. - Domestic clothing sales are projected to continue recovering, but the growth rate is expected to show marginal slowdown[200].